Systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases.
We are creating molecules that are systemically delivered, tissue-directed and locally active. We are advancing a pipeline of therapies that enable new approaches for patients with chronic viral infections, cancer, and other serious diseases.
PAYLOAD
TLR8 Agonist
TARGET & INDICATION(S)
Chronic Hepatitis B Virus
LEAD OP
PAYLOAD
Undisclosed
TARGET & INDICATION(S)
Preclinical
Our lead virology product candidate, SBT8230, is an ASGR1-TLR8 ImmunoTAC™ therapeutic. SBT8230 is engineered to potently activate human myeloid cells in the liver for the treatment of chronic hepatitis (cHBV). We believe liver-localized TLR8 agonism can best realize the potential for effective therapy and potentially lead to functional cures in patients suffering from cHBV.
Additional Discovery
In addition to SBT8230, we are evaluating additional ImmunoTAC™ conjugates that modulate important disease modifying pathways in diseases with unmet medical need.